chronic

Fangzhou Awarded Golden Bull Award for Leadership in AI-Powered Chronic Disease Management

XIAMEN, China, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of…

4 hours ago

Fangzhous XingJie LLM Completes Key National Filing, Setting Stage for Further AI-Driven Chronic Care Innovations

SHENZHEN, China, Nov. 02, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leader in AI-driven…

6 days ago

Berlin Heals Welcomes Dr. Eric Fain as New Board Member

Berlin Heals adds MedTech Veteran Dr. Eric Fain to Board of Directors Dr. Fain brings over 35 years of strategic…

2 weeks ago

Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

WALTHAM, Mass., Sept. 01, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory…

2 months ago

PEMF Therapy Emerges as a Leading 2025 Wellness Trend for Drug-Free Pain Relief; Grooni Earthings Pro Collection Meets Rising Demand

SHERIDAN, WY , Aug. 26, 2025 (GLOBE NEWSWIRE) -- As consumers seek science-informed, non-pharmacological options for chronic pain and recovery,…

2 months ago

Berlin Heals Announces Publication of Two-Year Clinical Outcomes of Cardiac Microcurrent Therapy in ESC Heart Failure

Study shows sustained improvements in heart failure symptoms and function following long-term C-MIC therapy ZUG, Switzerland, July 16, 2025 /PRNewswire/ -- Berlin…

4 months ago

CCS Presents Four Peer-Reviewed Posters at American Diabetes Associations 85th Scientific Sessions

CCS’s latest evidence-based research reinforces the most innovative and intelligent approaches to improving adherence and outcomes, while reducing the total…

5 months ago

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever…

5 months ago

Dupixent (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall…

5 months ago